pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Monjuvi
drug · antibody
save

tafasitamab

Phase 3updated 6mo ago
by $INCY INCYTE CORP🔗 ChEMBL
Phase 3
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 7 investigational indications.

indications

indications
DLBCL

targets

B-lymphocyte antigen CD19

all catalysts(0)

nothing on the calendar yet

Trials studying tafasitamab

  • phase2Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatmentrecruitingn=227
  • phase2To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)active not recruitingn=72
  • phase2Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphomarecruitingn=80
  • phase3A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.active not recruitingn=654
  • phase2TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphomanot yet recruitingn=30
  • phase2A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphomawithdrawn
  • phase2Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymrecruitingn=28
  • phase3Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patientsactive not recruitingn=899

News(4)

  • ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
    Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.
    fiercebiotech · 25d ago
  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
    AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…
    biospace · 1mo ago
  • Incyte cuts early-stage cancer drug to focus on next-gen programs
    Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
    biospace · 3mo ago
brand
Monjuvi
trade names
Minjuvi, Monjuvi, Monjuvi (tafasitamab-cxix) for injection
generic
tafasitamab
MOA
B-lymphocyte antigen CD19 binding agent
indication
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?